Novelix Pharmaceuticals Limited successfully conducted its Extra Ordinary General Meeting on January 9, 2026, addressing critical corporate governance matters through virtual participation. The meeting, held via video conferencing, demonstrated the company's commitment to maintaining transparent shareholder engagement while adhering to regulatory requirements.

Meeting Structure and Participation

The Extra Ordinary General Meeting commenced at 3:30 PM and concluded at 3:56 PM on January 9, 2026. A total of 64 members attended the meeting through Video Conferencing and Other Audio-Visual Means (OAVM), ensuring adequate representation for the proceedings.

Board and Leadership Attendance

The meeting witnessed comprehensive participation from the company's leadership team. Key attendees included Mr. Gattu Gnana Prakash as Director and Chairman, Mr. Venkateshwarlu Pulluru as Whole-time Director, and several other board members including Independent Director Mr. Janardhan Das Kabra and Director Mr. Jivamohan Divakar Valluri.

Additional participants comprised Ms. Sridevi Belide as Additional Director, Ms. Mayuri Baidya as Director, Ms. Nishita Kalantri as Company Secretary & Compliance Officer, and Ms. Bhoomika Choudhary as Chief Financial Officer. Mr. Bharat Khaniwal served as the appointed Scrutinizer for the voting process.

Key Agenda Items and Resolutions

The meeting focused on two primary business items, both requiring shareholder approval through electronic voting mechanisms. The agenda addressed strategic corporate decisions essential for the company's operational and governance framework.

E-Voting Process and Compliance

Novelix Pharmaceuticals implemented a comprehensive e-voting system to facilitate shareholder participation. The remote e-voting period extended from 9:00 AM on January 6, 2026, to 5:00 PM on January 8, 2026, providing members with adequate time to cast their votes.

The company engaged CDSL to provide the remote e-voting facility, ensuring technical reliability and security. Members who had not participated in remote e-voting were provided with an additional 15-minute e-voting window during the meeting itself. The combined results of both remote e-voting and meeting e-voting will be announced within 48 hours of the meeting's conclusion, with notifications sent to the stock exchange and publication on the company's website at www.novelixpharma.com .

Regulatory Compliance and Documentation

The meeting was conducted in full compliance with Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and the Companies Act, 2013. The company maintained proper documentation and notification procedures, ensuring all stakeholders received appropriate information regarding the meeting outcomes and voting results.

Sesha Sai Nikhil Chintalapati has disclosed the acquisition of equity shares in Novelix Pharmaceuticals Limited under SEBI's substantial acquisition regulations, marking a significant increase in his shareholding through preferential allotment.

Share Acquisition Details

The acquisition involved 4,92,000 equity shares obtained through preferential allotment on December 24, 2025. This transaction was disclosed in compliance with Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shareholding Pattern Changes

The acquisition resulted in a substantial change in Chintalapati's shareholding position in the pharmaceutical company. His voting rights percentage increased significantly following this transaction.

Company Capital Structure

Post-acquisition, Novelix Pharmaceuticals' capital structure reflects the expanded equity base. The company maintains a substantial warrant component in its diluted capital structure.

Persons Acting in Concert

The disclosure also identifies DM Fincon Services LLP as a person acting in concert (PAC) with the acquirer. DM Fincon Services LLP holds 20,000 shares representing 0.12% voting rights and 0.08% of total voting capital, with no change in their position during this acquisition.

Regulatory Compliance

The disclosure was made pursuant to SEBI regulations governing substantial acquisitions, ensuring transparency in shareholding changes above prescribed thresholds. The acquirer has fulfilled all mandatory disclosure requirements under the applicable regulations, providing detailed information about the transaction and resulting shareholding pattern to BSE Limited where the company's shares are listed under scrip code 536565.